Islet Sciences, Spring Point Project collaborate for transplantation trial

Spring Point Project’s team has experience under the current Good Manufacturing Practices required by US Food and Drug Administration regulations.

Islet Sciences chairman and CEO John Steel said the partnership is an important piece in the company’s strategy to initiate Islet transplantation trial using encapsulated Islet cells.

"We are pleased to announce this collaboration as we continue to add important Diabetes focused partners to our program," Steel added.

Spring Point Project’s 21,000ft² facility, the diabetes research and wellness Islet resource facility which was opened in February 2007, will support the trial.

Spring Point Project executive director Tom Spizzo said, "Our team and facility have the exceptional capabilities needed to support such a trial as Islet Sciences implements their novel scientific approach."